Comparison of Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Breakpoints for beta-Lactams in Enterobacteriaceae Producing Extended-Spectrum beta-Lactamases and/or Plasmid-Mediated AmpC beta-Lacta.
10.5145/KJCM.2011.14.1.24
- Author:
Wonkeun SONG
1
;
Min Jeong PARK
;
Han Sung KIM
;
Jae Seok KIM
;
Hyun Soo KIM
;
Kyu Man LEE
Author Information
1. Department of Laboratory Medicine, Hallym University College of Medicine, Seoul, Korea. swonkeun@hallym.or.kr
- Publication Type:Original Article
- Keywords:
CLSI;
EUCAST;
Enterobacteriaceae;
Breakpoint
- MeSH:
Aztreonam;
Bacterial Proteins;
beta-Lactamases;
beta-Lactams;
Carbapenems;
Cefotaxime;
Ceftazidime;
Cephalosporins;
Citrobacter freundii;
Enterobacter aerogenes;
Enterobacter cloacae;
Enterobacteriaceae;
Escherichia coli;
Imipenem;
Klebsiella oxytoca;
Klebsiella pneumoniae;
Proteus mirabilis;
Salmonella;
Serratia marcescens;
Shigella
- From:Korean Journal of Clinical Microbiology
2011;14(1):24-29
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: In 2010, the Clinical and Laboratory Standards Institute (CLSI) revised breakpoints for cephalosporins and carbapenems and indicated that extended-spectrum beta-lactamase (ESBL) testing is no longer necessary for Enterobacteriaceae. We compared the results of the CLSI 2010 and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC breakpoints for Enterobacteriaceae producing ESBL and/or plasmid-mediated AmpC beta-lactamase (PABL). METHODS: A total of 94 well-characterized clinical isolates of Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Salmonella spp., Shigella spp., Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, and Serratia marcescens were analyzed. Of them, 57 were ESBL producers, 24 were PABL producers, and 13 were ESBL plus PABL co-producers. Broth microdilution MIC tests were performed for cefotaxime, ceftazidime, aztreonam, cefepime, and imipenem. RESULTS: Among the 94 isolates containing ESBL and/or PABL, the number of isolates that were susceptible to cefotaxime, ceftazidime, aztreonam, cefepime, and imipenem according to the CLSI 2010 vs. the EUCAST breakpoints were 4 (4.3%) vs. 4 (4.3%); 26 (27.7%) vs. 8 (8.5%); 37 (39.4%) vs. 14 (14.9%); 71 (75.5%) vs. 31 (33.0%); and 76 (80.9%) vs. 90 (95.7%), respectively. Of the 18 isolates that were not susceptible to imipenem according to the CLSI 2010 breakpoints, 13 isolates (72.2%) were P. mirabilis. CONCLUSION: The CLSI 2010 MIC breakpoints without tests to detect ESBL and/or PABL for Enterobacteriaceae could be unreliable. Thus, special tests for ESBLs and AmpC beta-lactamases are required to detect the resistance mechanisms involved.
